Aromatase inhibitors: A review of clinical trials;Antiaromatases: Revue des résultats cliniques

Bulletin du Cancer

Volumn 87, Issue SPEC. ISS., 2000, Pages 31-39

  Kerbrat, P ^a   Lefeuvre, C ^a  

^a CENTRE EUGÈNE MARQUIS   (France)

Author keywords

Aromatase inhibitor; Breast cancer; Hormonal treatment

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; GESTAGEN; LETROZOLE; STEROID; VOROZOLE;

BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ENZYME INHIBITORS; FEMALE; HUMANS; NITRILES; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 0034469728     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Over expression of c-erb B2 is an independent marker of resistance to endoctine therapy in advanced breast cancer
2. BCAR 1/p130 Cas protein and primary breast cancer: Prognosis and reponse to tamoxifen treatment
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. First generation aromatase inhibitors. Amino glutethimide and testololactone
5. Low dose aminoglutethimide with and without hydrocortisone replacement as a first line endocrine treatment in advanced breast cancer: A prospective randomised trial of the IOGCR
6. Hormonal therapy of breast cancer
7. High versus standard dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association
8. Dose-response trial of megestrol acetate in advanced breast cancer: CALGB phase III study 8741
9. Tamoxifen versus oral MPA as initial endocrine therapy for patients with metastatic breast cancer; a Piedmont Oncology Association Study
10. Endocrine therapies of breast cancer
11. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors
12. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment
13. Exemestane experience in breast cancer treatment
14. Survival advantage of exemestane over megestrol acetate in post menopausal women with advanced breast cancer refractory to tamoxifen: Results of a phase III randomized double blind study
15. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex™) with megestrol acetate in postmenopausal patients with advanced breast cancer
16. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
17. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
18. The third-generation non steroidal aromatase inhibitions: A review of their clinical benefits in the record-line hormonal treatment of advanced breast cancer
19. Letrozole: A review of its use in postmenopausal women with advanced breast cancer
20. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
21. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2,5 mg daily, 0,5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
22. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor
23. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
24. A phase III trial comparing vorozole (Rivizor®) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer
25. Preliminary results of two multi-center trials comparing the efficacy and tolerability of Arimidex™ (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)
26. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer
27. Preliminary results of a large comparative multi-centre clinical trial comparing the efficacy and tolerability of Arimidex (anastrozole) and tamoxifen (TAM) in post menopausal women with advanced breast cancer (ABC)
28. Preliminary results of two multicenter trials comparing the efficacy and tolerablity of Arimidex™ (anastrozole) and tamoxifen in post menopausal women with advanced breast cancer
29. Combination hormonal therapy involving aromatases inhibitors in the management of women with breast cancer
30. Aromatase and its inhibitors: New biology and clinical perspectives
31. Pharmacokinetic interaction between letrozole and tamoxifene in post menopausal patient with advanced breast cancer
32. Cross resistance to different aromatase inhibitors in breast cancer treatment
33. Third-line hormonal treatment with exemestane in post-menopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
34. Multicenter phase II trial of exemestane as third-line hormonal therapy of post-menopausal women with metastatic breast cancer
35. Activity of exemestane in metastatic breast cancer after failure of non steroidal aromatase inhibitors: A phase II trial
36. Les antiaromatases
37. Adjuvant aminoglutethimide for post menopausal patients with primary breast cancer: Analysis at 8 years
38. Tamoxifen versus tamoxifen plus aminoglutethimide for stage I and II receptor positive post menopausal node-negative or node-positive breast cancer patients: Four-year results of a randomised trial of the Austrian Breast Cancer Study Group
39. Étude Atac: Implication pour les futurs essais dans le cancer du sein. Communication orale
40. Arimidex, tamoxifen alone or in combination adjuvant trial in post menopausal breast cancer
41. Traitement médical d'induction et cancer du sein
42. Aromatase within the breast
43. Intratumoral aromatase model: The effect of letrozole
44. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
45. Lessons from the use of aromatase inhibition in the neo-adjuvant setting